Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $18.9 million.

  • Cytek Biosciences' Cash from Investing Activities rose 21967.87% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.5 million, marking a year-over-year decrease of 64040.94%. This contributed to the annual value of -$83.0 million for FY2024, which is 1163.01% up from last year.
  • Per Cytek Biosciences' latest filing, its Cash from Investing Activities stood at $18.9 million for Q3 2025, which was up 21967.87% from -$16.4 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Cash from Investing Activities registered a high of $43.1 million during Q3 2023, and its lowest value of -$168.9 million during Q1 2023.
  • For the 5-year period, Cytek Biosciences' Cash from Investing Activities averaged around -$12.7 million, with its median value being -$1.3 million (2021).
  • Within the past 5 years, the most significant YoY rise in Cytek Biosciences' Cash from Investing Activities was 384991.3% (2023), while the steepest drop was 2155051.28% (2023).
  • Over the past 5 years, Cytek Biosciences' Cash from Investing Activities (Quarter) stood at -$18.3 million in 2021, then plummeted by 179.1% to -$51.1 million in 2022, then skyrocketed by 156.92% to $29.1 million in 2023, then plummeted by 318.24% to -$63.4 million in 2024, then skyrocketed by 129.83% to $18.9 million in 2025.
  • Its Cash from Investing Activities was $18.9 million in Q3 2025, compared to -$16.4 million in Q2 2025 and $9.5 million in Q1 2025.